Biotech News

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals (ADIL)Adial PharmaceuticalsCompany update

Allowed claims cover the detection of select genotypes for use of AD04 to treating AUD and OUD patients

CHARLOTTESVILLE, Va., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on...

Related news

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.

Recent company news

Stock data

Close
6.22 USD
Market cap
5.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States